Trial Profile

Pilot Study of Pemetrexed for the Treatment of Chordoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemetrexed (Primary)
Indications Chordoma
Focus Therapeutic Use

Most Recent Events

03 Mar 2023 Status changed from active, no longer recruiting to completed.
08 Mar 2022 Status changed from recruiting to active, no longer recruiting.
14 Jan 2020 According to a Pacific Neuroscience Institute media release, the trial is now recruiting patients at Providence Saint John's Health Center's Pacific Brain Tumor Center. Positive results may spur the expansion of the trial beyond the single location in Santa Monica. Eli Lilly and Company is providing the drug and funding for the study.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com